We and others have shown that acute (i.e., days) treatment with the inflammatory cytokine, interleukin-1 (IL-1), is sufficient to represses AR and AR target gene expression in PCa cells while concomitantly upregulating other prosurvival proteins and pathways [12,13,14,15,16]. The gene discussed is IL1A; the disease is posterior cortical atrophy.